関節リウマチ患者におけるupadacitinib または adalimumab の3年間の長期有効性: SELECT-COMPARE 試験

RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012

Upadacitinib continues to show consistently better clinical responses, compared with adalimumab, through 3 years, including rates of remission and low disease activity, physical function and pain severity.Following the favourable upadacitinib efficacy data seen in the SELECT-COMPARE study at 72 weeks, Fleischmann, et al. assessed the long-term safety and efficacy of upadacitinib versus adalimumab over 3 years in the long-term extension of this study, with promising results.

Keywords:


Publication thumbnail: 関節リウマチ患者におけるupadacitinib または adalimumab の3年間の長期有効性: SELECT-COMPARE 試験
LinkedIn